Skip to main content

Table 1 Demographics and baseline characteristics of participants ≥60 years of age and overall population

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

  Overall pooled population Participants ≥60 years of age
Quarterly fremanezumab
n = 943
Monthly fremanezumab
n = 954
Placebo
n = 945
Quarterly fremanezumab
n = 74
Monthly fremanezumab
n = 92
Placebo
n = 80
Age, years, mean (SD) 42.8 (11.83) 43.0 (12.09) 42.9 (12.02) 63.5 (2.96) 63.2 (3.15) 64.0 (2.83)
Female, n (%) 811 (86) 813 (85) 808 (86) 60 (81) 77 (84) 67 (84)
White, n (%) 787 (83) 804 (84) 787 (83) 71 (96) 81 (88) 70 (88)
BMI, kg/m2, mean (SD) 26.3 (4.98) 26.0 (4.94) 26.4 (4.81) 25.5 (4.14) 25.7 (4.18) 26.0 (4.01)
Migraine classification, n (%)
 Chronic migraine 545 (58) 553 (58) 541 (57) 56 (76) 46 (50) 45 (56)
 Episodic migraine 398 (42) 401 (42) 404 (43) 18 (24) 46 (50) 35 (44)
Time since initial migraine diagnosis, years, mean (SD) 21.1 (12.77) 21.5 (12.88) 21.2 (12.92) 37.3 (13.06) 38.0 (12.31) 37.1 (12.49)
  1. SD, standard deviation; BMI, body mass index